Original ContributionsIron accumulation in the substantia nigra in rats visualized by ultrasound
Introduction
In recent studies, we were able to show different patterns of substantia nigra (SN) echogenicity in human beings using trasncranial ultrasound (for details see Becker and Bogdahn 1993, Bogdahn et al 1998). In patients with Parkinson’s disease (PD), we have found a marked increase of SN echogenicity (Becker et al. 1995). This hyperechogenicity was attributed to either an increase of iron Dexter et al 1989, Dexter et al 1993, Gerlach et al 1994, Hirsch et al 1991, Riederer et al 1989, Sofic et al 1988, Sofic et al 1991, Wang et al 1995 or a change of the cytoarchitecture and glial-cell composition of the SN due to the degenerative changes that are known to occur in PD Barron 1995, Montine et al 1995. However, gliosis in the SN in PD is only mild, and histopathological findings disclosed more a cell loss than a profound increase in cell density. Interestingly, a hyperechogenicity of the SN was also detected in about 9% of healthy subjects in a group of 420 volunteers (unpublished data). This observation once more raised the question about the etiology of the change of SN echogenicity. Keeping in mind that animal models can only give limited insights into the pathology of PD, we tested if trace metals like iron or iron-binding proteins could lead to a change in SN echogenicity by performing ultrasound examinations in a rat model, followed by a spectroscopic measurement of iron in the SN of both sides.
Section snippets
Animal preparation
Wistar rats, 3–4 months old, were housed under controlled temperature and light conditions. They were anesthetized with chloral hydrate. Rat brains were injected stereotactically into the right SN with:
- 1.
iron in the concentration of 0.3, 1.5 and 7.5 μg of FeCl3 (in 2 μl tris-citrate buffer);
- 2.
ferritin (3.2 μg ferritin in 2 μl tris-citrate buffer), to mimic possible alterations of protein-bound iron;
- 3.
6-OH-dopamine (6-OHDA) (1μg and 8μg 6-OHDA in 2 μl saline 0.9% and 0.02% ascorbate), which is known
Ultrasound findings
Echogenicity of the right SN and adjacent areas increased with the concentration of iron injected (Fig. 1). After the injection of low concentrations of iron (0.3 μg), a slight increase of echogenicity was realized; after injection of 1.5 and 7.5 μg of iron, echogenicity was marked. Additionally, a wider spread of the dose–dependent inreasingly echogenic signal could be visualized. At the lowest concentration, the signal was restricted to the area of the SN, at 1.5 μg, close adjacent brain
Discussion
This pilot study demonstrates a dose–dependent increase of SN echogenicity for iron in different concentrations and, partly, for 6-OHDA in different concentrations that corresponded to a dose–dependent increase of iron in the injected SN measured by spectroscopy. This is in accordance with the hypothesis of an increase of SN echogenicity due to iron accumulation. Because the amount of iron measured by spectroscopy was only slightly higher after the injection of 8 μg compared with the injection
References (29)
The microglial cell. A historical review
J Neurol Sci
(1995)- et al.
Dopamine, 6-hydroxydopamine, iron, and dioxygen—their mutual interactions and possible implication in the development of Parkinson’s disease
Biochim Biophys Acta
(1996) - et al.
Transcranial color-coded real-time sonography
- et al.
Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real-time sonography
Neurology
(1995) - et al.
The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons
J Neurochem
(1991) - et al.
Parenchymanatomie
- et al.
Cellular distribution of transferrin, ferritin and iron in normal and aged human brains
J Neurosci Res
(1990) - et al.
Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia
Brain
(1991) - et al.
Implications of alterations in trace element levels in brain in Parkinson’s disease and other neurological disorders affecting the basal ganglia
Adv Neurol
(1993) - et al.
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease
J Neurochem
(1989)
In vitro studies of ferritin iron release and neurotoxicity
J Neurochem
Altered brain metabolism of iron as a cause of neurodegenerative diseases?
J Neurochem
Animal models of Parkinson’s diseasean empirical comparison with the phenomenology of the disease in man
J Neural Trnasm
The effect of age on the nonhaem iron in the human brain
J Neurochem
Cited by (155)
Digitized Image Analysis of Insula Echogenicity Detected by TCS-MR Fusion Imaging in Wilson's and Early-Onset Parkinson's Diseases
2020, Ultrasound in Medicine and BiologyTranscranial B-Mode Sonography in Movement Disorders
2018, International Review of NeurobiologyIron accumulation and microglia activation contribute to substantia nigra hyperechogenicity in the 6-OHDA-induced rat model of Parkinson's disease
2017, Parkinsonism and Related DisordersAdults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism
2016, Parkinsonism and Related Disorders